Taiwan Biomaterial Co., Ltd. (TPEX:6649)
37.50
-0.40 (-1.06%)
Jul 30, 2026, 1:30 PM CST
Taiwan Biomaterial Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,592 | 1,953 | 1,436 | 1,315 | 1,457 | 818 | |
Market Cap Growth | -8.23% | 35.97% | 9.26% | -9.80% | 78.08% | -16.50% |
Enterprise Value | 1,338 | 1,643 | 1,195 | 1,060 | 1,212 | 726 |
Last Close Price | 37.90 | 45.42 | 33.41 | 30.58 | 33.70 | 24.08 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 61.83 | 33.14 | - | - | 43.18 | - |
PS Ratio | 8.88 | 8.86 | 14.87 | 18.05 | 11.45 | 19.64 |
PB Ratio | 2.47 | 2.85 | 2.29 | 2.09 | 2.26 | 1.94 |
P/TBV Ratio | 2.48 | 2.86 | 2.30 | 2.10 | 2.26 | 1.94 |
P/FCF Ratio | 105.00 | 41.27 | 97.44 | - | - | - |
P/OCF Ratio | 89.40 | 40.04 | 77.95 | - | 49.73 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 7.47 | 7.46 | 12.37 | 14.55 | 9.52 | 17.42 |
EV/EBITDA Ratio | 31.81 | 22.83 | 1206.78 | - | 33.65 | - |
EV/EBIT Ratio | 50.22 | 27.01 | - | - | 47.59 | - |
EV/FCF Ratio | 88.23 | 34.72 | 81.05 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.08 | 0.08 | 0.09 | 0.10 | 0.11 | 0.18 |
Debt / EBITDA Ratio | 1.22 | 0.69 | 10.26 | 22.21 | 1.65 | - |
Debt / FCF Ratio | 3.40 | 1.11 | 3.87 | - | - | - |
Net Debt / Equity Ratio | -0.39 | -0.44 | -0.41 | -0.39 | -0.41 | -0.19 |
Net Debt / EBITDA Ratio | -6.78 | -4.21 | -258.43 | 106.60 | -7.33 | 1.52 |
Net Debt / FCF Ratio | -16.77 | -6.41 | -17.36 | 19.12 | 41.52 | 1.45 |
Asset Turnover | 0.24 | 0.30 | 0.14 | 0.10 | 0.20 | 0.07 |
Inventory Turnover | 1.50 | 1.71 | 0.88 | 0.78 | 2.66 | 1.20 |
Quick Ratio | 4.25 | 7.14 | 12.61 | 9.71 | 12.81 | 2.44 |
Current Ratio | 5.51 | 8.53 | 14.39 | 11.30 | 13.74 | 2.77 |
Return on Equity (ROE) | 4.00% | 8.99% | -0.28% | -1.59% | 6.31% | -10.64% |
Return on Assets (ROA) | 2.21% | 5.09% | -0.99% | -1.23% | 2.47% | -6.30% |
Return on Capital Employed (ROCE) | 3.80% | 8.30% | -1.70% | -2.10% | 3.60% | -11.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 1.63% | 3.02% | -0.12% | -0.77% | 2.32% | -5.80% |
FCF Yield | 0.95% | 2.42% | 1.03% | -0.97% | -0.44% | -6.64% |
Dividend Yield | 2.69% | 2.20% | - | - | 0.59% | - |
Buyback Yield / Dilution | 0.01% | - | - | -2.73% | -23.90% | - |
Total Shareholder Return | 2.70% | 2.20% | - | -2.73% | -23.30% | - |